Prelude Therapeutics’ (PRLD) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Prelude Therapeutics (NASDAQ:PRLD) in a research report released on Tuesday morning,Benzinga reports. HC Wainwright currently has a $5.00 price target on the stock. HC Wainwright also issued estimates for Prelude Therapeutics’ Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.33) EPS, FY2025 earnings at ($1.51) EPS, Q1 2026 earnings at ($0.30) EPS, Q2 2026 earnings at ($0.31) EPS, Q3 2026 earnings at ($0.31) EPS, Q4 2026 earnings at ($0.32) EPS and FY2026 earnings at ($1.24) EPS.

Separately, JMP Securities reduced their price objective on Prelude Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research report on Monday, August 18th. Two research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $4.00.

Prelude Therapeutics Trading Up 4.3%

Shares of PRLD stock opened at $1.22 on Tuesday. The stock has a 50 day moving average of $1.02 and a two-hundred day moving average of $0.90. Prelude Therapeutics has a 12 month low of $0.61 and a 12 month high of $2.25. The company has a market capitalization of $69.05 million, a P/E ratio of -0.74 and a beta of 1.25.

Prelude Therapeutics (NASDAQ:PRLD) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.04. Sell-side analysts predict that Prelude Therapeutics will post -1.81 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Prelude Therapeutics

A number of hedge funds have recently modified their holdings of PRLD. BNP Paribas Financial Markets acquired a new position in shares of Prelude Therapeutics in the 4th quarter worth approximately $26,000. Deutsche Bank AG raised its holdings in shares of Prelude Therapeutics by 747.6% in the 4th quarter. Deutsche Bank AG now owns 123,899 shares of the company’s stock worth $159,000 after buying an additional 109,281 shares in the last quarter. Millennium Management LLC increased its holdings in Prelude Therapeutics by 188.2% during the 4th quarter. Millennium Management LLC now owns 462,555 shares of the company’s stock valued at $590,000 after purchasing an additional 302,031 shares in the last quarter. Two Sigma Advisers LP increased its holdings in Prelude Therapeutics by 526.3% during the 4th quarter. Two Sigma Advisers LP now owns 300,000 shares of the company’s stock valued at $382,000 after purchasing an additional 252,100 shares in the last quarter. Finally, Two Sigma Investments LP increased its holdings in Prelude Therapeutics by 307.2% during the 4th quarter. Two Sigma Investments LP now owns 231,839 shares of the company’s stock valued at $296,000 after purchasing an additional 174,906 shares in the last quarter. 79.72% of the stock is owned by institutional investors and hedge funds.

Prelude Therapeutics Company Profile

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.